{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:33:06Z","timestamp":1793640786701,"version":"4.5.1"},"reference-count":39,"publisher":"Informa UK Limited","issue":"11","license":[{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"funder":[{"name":"the science and technology innovation Program of Hunan Province","award":["2023SK4024"],"award-info":[{"award-number":["2023SK4024"]}]},{"name":"Hunan Provincial Natural Science Foundation of China","award":["2026JJ30152"],"award-info":[{"award-number":["2026JJ30152"]}]},{"name":"the Hunan Cancer Hospital Climb plan","award":["ZX2020005-5"],"award-info":[{"award-number":["ZX2020005-5"]}],"id":[{"id":"https:\/\/ror.org\/025020z88","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Biological Therapy"],"published-print":{"date-parts":[[2026,11,2]]},"DOI":"10.1080\/14712598.2026.2742404","type":"journal-article","created":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T02:56:13Z","timestamp":1792205773000},"page":"1185-1196","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["An evaluation of sacituzumab tirumotecan for the treatment of NSCLC"],"prefix":"10.1080","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8306-6395","authenticated-orcid":false,"given":"Jingyi","family":"Wang","sequence":"first","affiliation":[{"name":"The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University\/Hunan Cancer Hospital","place":["Changsha, China"]},{"name":"Xiangya Hospital, Central South University","place":["Changsha, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3647-9901","authenticated-orcid":false,"given":"Yu","family":"Zhou","sequence":"additional","affiliation":[{"name":"The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University\/Hunan Cancer Hospital","place":["Changsha, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7078-7767","authenticated-orcid":false,"given":"Lin","family":"Wu","sequence":"additional","affiliation":[{"name":"The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University\/Hunan Cancer Hospital","place":["Changsha, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,10,21]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.70090"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.106034"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2026.0017"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.21037\/atm-22-4444"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00408-025-00801-x"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-024-00660-7"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2024.116378"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-025-04834-0"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.15647"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.25615"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2025.117863"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.951589"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03638-2"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2025-085680"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2026.106960"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03883-5"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.08.2573"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2512071"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(26)00968-2"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40291-021-00563-1"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-025-01085-z"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.12.009"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.10613"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(23)00135-2"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.10.117"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.8506"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.4318"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-21-0206"},{"key":"e_1_3_5_31_1","unstructured":"Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. Sacituzumab tirumotecan for injection: prescribing information [Internet]. 2026 [cited 2026 Sep 19]. Available from: https:\/\/www.kelun-biotech.com\/upload\/2026-03-10\/108400283.pdf"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-025-01705-2"},{"key":"e_1_3_5_33_1","unstructured":"Merck & Co. Inc. FDA grants breakthrough therapy designation to sacituzumab tirumotecan (sac-TMT) for the treatment of certain patients with previously treated advanced or metastatic nonsquamous non-small cell lung cancer with EGFR mutations [Internet]. 2024 Dec 3 [cited 2026 Sep 19]. Available from: https:\/\/www.merck.com\/news\/fda-grants-breakthrough-therapy-designation-to-sacituzumab-tirumotecan-sac-tmt-for-the-treatment-of-certain-patients-with-previously-treated-advanced-or-metastatic-nonsquamous-non-small-cell-lung-ca\/"},{"key":"e_1_3_5_34_1","unstructured":"Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. Voluntary announcement: core product sacituzumab tirumotecan (sac-TMT) approved for marketing for a second indication by the National Medical Products Administration in EGFRm NSCLC [Internet]. 2025 Mar 10 [cited 2026 Sep 19]. Available from:https:\/\/www1.hkexnews.hk\/listedco\/listconews\/sehk\/2025\/0310\/2025031000450.pdf"},{"key":"e_1_3_5_35_1","unstructured":"Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. Voluntary announcement: core product sacituzumab tirumotecan (sac-TMT) approved for marketing for a third indication by the National Medical Products Administration in EGFRm NSCLC following progression on EGFR-TKI therapy [Internet]. 2025 Oct 12 [cited 2026 Sep 19].Available from: https:\/\/www1.hkexnews.hk\/listedco\/listconews\/sehk\/2025\/1012\/2025101200011.pdf"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00733"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-01544"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2024.2409621"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2023-0230"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102572"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-026-01523-w"}],"container-title":["Expert Opinion on Biological Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14712598.2026.2742404","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/14712598.2026.2742404","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14712598.2026.2742404","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:23:20Z","timestamp":1793640200000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14712598.2026.2742404"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,21]]},"references-count":39,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11,2]]}},"alternative-id":["10.1080\/14712598.2026.2742404"],"URL":"https:\/\/doi.org\/10.1080\/14712598.2026.2742404","relation":{},"ISSN":["1471-2598","1744-7682"],"issn-type":[{"value":"1471-2598","type":"print"},{"value":"1744-7682","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,21]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-07-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}